Efficacy of fremanezumab in migraine patients with medication overuse and documented inadequate response to 2-4 migraine preventive medications: subgroup analysis of the randomised, placebo-controlled FOCUS study

被引：0
|
作者：
Silberstein, Stephen [1 ]
Cohen, Joshua M. [2 ]
Ramirez-Campos, Verena [2 ]
Yang, Ronghua [2 ]
Galic, Maja [3 ]
Ning, Xiaoping [2 ]
Jann, Adelene [4 ]
机构：
[1] Jefferson Headache Ctr, Philadelphia, PA USA
[2] Teva Pharmaceut Ind, Frazer, PA USA
[3] Teva Pharmaceut, Amsterdam, Netherlands
[4] NYU Langone Hlth, New York, NY USA
来源：
CEPHALALGIA | 2019年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
IHC-PO-156
引用
收藏
页码：226 / 227
页数：2
相关论文
共 50 条
  • [41] Reduction in migraine days with aura with fremanezumab in patients with documented inadequate response to 2-4 classes of migraine preventive medications in the focus study
    Ashina, M.
    Cohen, J. M.
    Yang, R.
    Ramirez-Campos, V.
    Seminerio, M.
    Lampl, C.
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2019, 405
  • [42] Efficacy of fremanezumab in patients with migraine and documented inadequate response to 2, 3, or 4 classes of migraine preventive treatments: results of the international, multicenter, randomised, placebo-controlled FOCUS study
    Pazdera, Ladislav
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [43] Improvements in Headache-Related Disability with Fremanezumab Treatment in Patients with Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications in the Randomized, Placebo-Controlled FOCUS Study
    Ashina, Messoud
    Ferrari, Michel D.
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    ANNALS OF NEUROLOGY, 2019, 86 : S76 - S77
  • [44] Efficacy of fremanezumab in patients with migraine and documented inadequate response to valproic acid and 2-3 other classes of migraine preventive medications in the international, multicentre, randomised, placebo-controlled FOCUS study
    Pazdera, L.
    Ning, X.
    Galic, M.
    Cohen, J. M.
    Yang, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2019, 26 : 633 - 633
  • [45] Early Onset of Efficacy With Fremanezumab in Patients With Medication Overuse and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Treatments: Subgroup Analysis of the Randomized, Double-blind FOCUS Study
    Katsarava, Zaza
    Machkova, Martina
    Ramirez-Campos, Verena
    Cohen, Joshua M.
    Janka, Lindsay
    Spierings, Egilius
    NEUROLOGY, 2020, 94 (15)
  • [46] Very Early Onset of Action of Fremanezumab in Patients With Migraine and Documented Inadequate Response to 2-4 Classes of Migraine Preventive Medications: Results of the International, Multicenter, Randomized, Placebo-controlled FOCUS Study
    Brandes, Jan Lewis
    Ramirez-Campos, Verena
    Yang, Ronghua
    Cohen, Joshua
    Galic, Maja
    Ning, Xiaoping
    Treppendahl, Christina
    NEUROLOGY, 2020, 94 (15)
  • [47] Very early onset of action of fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    Brandes, Jan
    Ramirez-Campos, Verena
    Yang, Ronghua
    Cohen, Joshua M.
    Galic, Maja
    Ning, Xiaoping
    Treppendahl, Christina
    CEPHALALGIA, 2019, 39 : 11 - 12
  • [48] Efficacy, clinically meaningful responses, and impact on acute headache medication use with fremanezumab in patients with migraine and documented inadequate response to 2-4 classes of migraine preventive treatments: results of the international, multicentre, randomised, placebo-controlled FOCUS study
    Ferrari, Michel D.
    Diener, Hans Christoph
    Spierings, Egilius L. H.
    Ning, Xiaoping
    Galic, Maja
    Cohen, Joshua M.
    Yang, Ronghua
    Ashina, Messoud
    JOURNAL OF HEADACHE AND PAIN, 2020, 21 (SUPPL 1):
  • [49] Efficacy of Fremanezumab in Migraine Patients With Pain or Psychiatric Comorbidities and Documented Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
    Spierings, E. L. H.
    Ning, X.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 18 - 18
  • [50] Efficacy of Fremanezumab in Migraine Patients With Pain or Psychiatric Comorbidities and Documented Inadequate Response to 2-4 Prior Migraine Preventive Medication Classes
    Spierings, E. L. H.
    Ning, X.
    Cohen, J. M.
    Campos, V. Ramirez
    Barash, S.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 26 - 27
12345